Polyethylene Glycol
| Evidence Level: L5 | Predicted Indications: 1 |
Table of Contents
- Polyethylene Glycol
- Polyethylene Glycol: From Constipation and Dry Eye to Congenital Ichthyosiform Erythroderma
Polyethylene Glycol: From Constipation and Dry Eye to Congenital Ichthyosiform Erythroderma
One-Sentence Summary
Polyethylene glycol (PEG) is a hydrophilic polymer originally used as an osmotic laxative for constipation and as a lubricant in eye drops for dry eye. The TxGNN model predicts it may be effective for congenital ichthyosiform erythroderma, but there are currently 0 clinical trials and 0 publications supporting this direction, so the prediction rests on the model alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Constipation, dry eye syndrome, xerophthalmia (from the knowledge graph; no approved indication text is available on the New Zealand licence) |
| Predicted New Indication | Congenital ichthyosiform erythroderma |
| TxGNN Prediction Score | 99.03% |
| Evidence Level | L5 |
| New Zealand Market Status | Cancelled only |
| Number of Authorizations | 1 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on known information, polyethylene glycol is a hydrophilic polymer used as an osmotic laxative, as an ophthalmic lubricant, and as a vehicle in topical products. Its efficacy in constipation and dry eye is established, and it may, in a limited way, be applicable to a skin condition through its moisturising properties.
A speculative rationale is that PEG has humectant and emollient-like properties, so it could in principle support skin barrier hydration in ichthyosis. This has not been validated. Congenital ichthyosiform erythroderma is a genetic keratinisation disorder (for example, variants in TGM1, ALOXE3, ALOX12B or NIPAL4) driven by defects in the skin barrier and lipid metabolism, not by dehydration alone. At most, PEG could be a symptomatic or vehicle-level contributor, not a disease-modifying agent. The model's specificity for this particular disease is not explained by this reasoning.
The oral osmotic laxative and ophthalmic lubricant uses have no evident mechanistic connection to this skin disease.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
New Zealand Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 2640120 | Systane Unit Dose | Eye drops 0.4% and propylene glycol 0.3%, 0.8 ml | Not stated (licence cancelled) |
Safety Considerations
Package insert warnings and contraindications were not available for this report, so please refer to the package insert for safety information.
The following contraindication-related associations come from the knowledge graph (drug-disease links), not from label text, and should be verified against the official product information:
- Cardiovascular and fluid/electrolyte conditions: hypertension, congestive heart failure, cardiovascular disease, heart disease, potassium deficiency, hypercalcaemia, phosphorus metabolism disease
- Renal conditions: kidney disease, anuria, nephrocalcinosis, pyoureter
- Gastrointestinal conditions: ileus, paralytic ileus, intestinal obstruction, pyloric stenosis, toxic megacolon, familial visceral myopathy, appendicitis
- Metabolic and endocrine conditions: diabetes mellitus, hyperglycaemia, diabetic ketoacidosis, hyperthyroidism, Graves disease, thyrotoxicosis
- Neurological conditions: epilepsy
- Eye conditions: angle-closure (closed-angle) glaucoma, eye infectious disease, conjunctivitis
No drug interaction records were found.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction is model-based only (L5), with no clinical trials or publications. The proposed mechanism is speculative and does not explain specificity for congenital ichthyosiform erythroderma. The only New Zealand licence is cancelled, and safety data are incomplete.
To proceed, the following is needed:
- Mechanism of action data for PEG
- Preclinical or clinical evidence in ichthyosis (literature and trial searches)
- Assessment of route compatibility (a topical formulation would be needed, and none is currently identified)
- Package insert warnings and contraindications from Medsafe
- Clarification of the cancelled licence status and any currently marketed PEG products in New Zealand
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.